GET DAILY SIGNALSCalidi Biotherapeutics (CLDI) and the Road to $1: Evaluating a +54% Recovery Opportunity
Key Takeaways
- This analysis looks at a $1 price target drawn from public discussion and a psychological round-number recovery level, not from any credible analyst consensus.
- CLDI trades near $0.65, so a move to $1 would require roughly a 54% advance — a meaningful shift for this beaten-down micro-cap name.
- Analyst coverage is virtually nonexistent; reported single-analyst figures range wildly from around $10 to over $1,900 and appear influenced by stale data or reverse splits, so no reliable analyst price target exists.
- Supportive elements include the company’s immuno-oncology pipeline, particularly lead candidate CLD-401, along with positive pre-IND feedback from the FDA.
- Major risks center on near-zero revenue, ongoing cash burn, repeated dilution, and a share price that has dropped roughly 95% over the past year.
- Readers can review Major News, Today’s Price Move, a detailed Forecast, and upcoming Earnings on dedicated pages.
How the $1 Target Emerged
CLDI lacks any meaningful, verifiable analyst consensus. Public data shows contradictions, with some sources citing a lone target near $120, others above $1,900, and MarketScreener listing a Baird figure around $10. These inconsistencies largely stem from reverse stock splits and outdated estimates rather than current research. In the absence of a credible aggregate, the $1 level functions as a fallback target rooted in public market conversation — a commonly referenced psychological and recovery milestone for a stock trading well below one dollar.
Current Market Position and Path to the Target
At the latest verified price near $0.65, reaching $1 implies upside of about 54%. The 52-week range of roughly $0.62 to $24.96 highlights how far shares have declined, driven largely by dilution from repeated capital raises typical of pre-revenue biotechnology firms. Any path toward $1 would likely hinge on successful financing, progress advancing CLD-401 into clinical trials, and stabilization in share count and daily trading volume. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Factors That Could Support a Move Higher
Calidi’s lead candidate, CLD-401, an IL-15 superagonist, remains in IND-enabling studies targeting metastatic solid tumors such as non-small cell lung cancer and head and neck cancer. The company has received positive pre-IND feedback from the FDA and has discussed first patient dosing potentially in early 2027. Additional programs, including CLD-101 for high-grade glioma and CLD-201 for solid tumors, expand the pipeline. Any favorable regulatory update, well-received financing, or renewed interest in immuno-oncology could help improve sentiment.
Obstacles That Could Block the Target
Challenges remain substantial. Calidi generates essentially no revenue and reports negative EPS, requiring repeated capital raises to fund operations. This creates ongoing dilution risk and has contributed significantly to the share-price collapse. Failure to secure funding, delays in the clinical timeline, or another reverse split could all hinder a sustained advance toward $1. Micro-cap biotech stocks also face high volatility and limited institutional ownership.
Technical Levels and Market Structure
The $1 mark stands out as a prominent psychological round number that would likely serve as natural resistance if approached. The 52-week low near $0.62 offers a key support level, while the stock continues in a long-term downtrend well below prior highs. Thin average daily volume around 100,000 shares means even modest buying or selling can trigger outsized moves, reducing the reliability of near-term technical signals. From what I see, monitoring volume trends closely remains important here.
Time Horizon and Key Items to Watch
Since the $1 objective comes from public discussion rather than a formal analyst price forecast, no specific research horizon applies. Investors should track the next earnings release, updates on CLD-401’s IND submission and first-patient timing, any new financing or share issuance, changes to share count from reverse splits, and broader biotechnology sector sentiment. Federal Reserve rate expectations can also shape appetite for speculative, cash-burning companies. I’m watching this closely as clinical and financing updates arrive.
Incorporating AI Signals into My Research
In my research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to gain an additional perspective on names like this. The platform uses artificial intelligence to monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions and technical behavior. For a low-priced, high-volatility stock such as CLDI, these signals can help identify opportunities and spot potential trend shifts more efficiently.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CLDI's RSI Indicator ascends from oversold territory
The RSI Oscillator for CLDI moved out of oversold territory on November 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 44 similar instances when the indicator left oversold territory. In 29 of the 44 cases the stock moved higher. This puts the odds of a move higher at 66%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 33 of 71 cases where CLDI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 46%.
The Moving Average Convergence Divergence (MACD) for CLDI just turned positive on October 30, 2026. Looking at past instances where CLDI's MACD turned positive, the stock continued to rise in 20 of 44 cases over the following month. The odds of a continued upward trend are 45%.
Following a +7.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLDI advanced for three days, in 67 of 136 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.
CLDI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLDI as a result. In 59 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLDI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CLDI entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.577) is normal, around the industry mean (3.498). P/E Ratio (-0.019) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. CLDI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLDI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement